No black box warning on record for Vyxeos

As of the latest FDA labeling reviewed, Vyxeos ((DAUNORUBICIN AND CYTARABINE) LIPOSOME) does not carry a black box warning. Standard warnings and precautions still apply — see the full Vyxeos medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hemorrhage: Serious or fatal hemorrhagic events with associated prolonged thrombocytopenia have occurred with VYXEOS. Monitor blood counts regularly until recovery. ( 5.2 ) • Cardiotoxicity: VYXEOS treatment is not recommended in patients with cardiac function that is less than normal. Discontinue VYXEOS in patients with impaired cardiac function unless the benefit of

No black box warning on record for Vyxeos

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hemorrhage: Serious or fatal hemorrhagic events with associated prolonged thrombocytopenia have occurred with VYXEOS. Monitor blood counts regularly until recovery. ( 5.2 ) • Cardiotoxicity: VYXEOS treatment is not recommended in patients with cardiac function that is less than normal. Discontinue VYXEOS in patients with impaired cardiac function unless the benefit of

Vyxeos Black Box Warning

No black box warning on record for Vyxeos

Other warnings & precautions

Vyxeos Black Box Warning

No black box warning on record for Vyxeos

Other warnings & precautions